- Home
- ALGS vs ANVS Comparison
ALGS vs ANVS Comparison
Compare ALGS & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- ANVS
- Stock Information
- Founded
- ALGS 2018
- ANVS 2008
- Country
- ALGS United States
- ANVS United States
- Employees
- ALGS N/A
- ANVS 6
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- ALGS Health Care
- ANVS Health Care
- Exchange
- ALGS Nasdaq
- ANVS Nasdaq
- Market Cap
- ALGS 53.0M
- ANVS 55.5M
- IPO Year
- ALGS 2020
- ANVS 2020
- Fundamental
- Price
- ALGS $9.13
- ANVS $2.89
- Analyst Decision
- ALGS Strong Buy
- ANVS Strong Buy
- Analyst Count
- ALGS 1
- ANVS 4
- Target Price
- ALGS $70.00
- ANVS $18.00
- AVG Volume (30 Days)
- ALGS 84.2K
- ANVS 344.4K
- Earning Date
- ALGS 08-05-2025
- ANVS 08-14-2025
- Dividend Yield
- ALGS N/A
- ANVS N/A
- EPS Growth
- ALGS N/A
- ANVS N/A
- EPS
- ALGS N/A
- ANVS N/A
- Revenue
- ALGS $3,270,000.00
- ANVS N/A
- Revenue This Year
- ALGS N/A
- ANVS N/A
- Revenue Next Year
- ALGS $51.55
- ANVS N/A
- P/E Ratio
- ALGS N/A
- ANVS N/A
- Revenue Growth
- ALGS N/A
- ANVS N/A
- 52 Week Low
- ALGS $3.76
- ANVS $1.11
- 52 Week High
- ALGS $46.80
- ANVS $11.29
- Technical
- Relative Strength Index (RSI)
- ALGS 59.79
- ANVS 58.30
- Support Level
- ALGS $8.18
- ANVS $2.63
- Resistance Level
- ALGS $9.44
- ANVS $2.89
- Average True Range (ATR)
- ALGS 0.71
- ANVS 0.23
- MACD
- ALGS 0.01
- ANVS 0.01
- Stochastic Oscillator
- ALGS 65.95
- ANVS 83.08
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.